Featured Research

from universities, journals, and other organizations

Cancer Vaccines Led To Long-term Survival For Patients With Metastatic Melanoma

Date:
July 29, 2009
Source:
Hoag Memorial Hospital Presbyterian
Summary:
Medical researchers have released promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.

Hoag Memorial Hospital Presbyterian has announced promising data from a clinical study showing patient-specific cancer vaccines derived from patients' own cancer cells and immune cells were well tolerated and resulted in impressive long-term survival rates in patients with metastatic melanoma whose disease had been minimized by other therapies.

Related Articles


"There is continued interest in developing new therapies for melanoma patients with recurrent or distant metastatic disease at the time of diagnosis because there are no systemic therapies that can be relied upon to cure them," said Robert O. Dillman, M.D., F.A.C.P., executive medical and scientific director at the Hoag Cancer Center and lead investigator for the study. "Patients with metastatic melanoma are at high risk for additional metastases and death."

During the study, 54 patients with regionally recurrent or distant metastatic melanoma were injected with a vaccine that included each patient's own immune cells (dendritic cells) and 500 micrograms of granulocyte-colony stimulating factor (GM-CSF), an immune stimulator, three times a week and then monthly for five months for a total of up to eight injections. The patient's dendritic cells were obtained from their peripheral blood and mixed with a cell culture of the patient's own melanoma cells that had been self-renewing and proliferating in the laboratory. The patient-specific vaccine is designed to stimulate the patient's immune system to react against tumor stem cells or early progenitor cells that can create new depots of cancer throughout the body.

Data showed that the projected five-year survival rate is 54% at a median follow up of 4.5 years (range 2.4 to 7.4) for the 30 surviving patients. Although not a direct comparison, the results are superior to those observed following vaccination with irradiated tumor cells in 48 melanoma patients in a previous trial (64 vs. 31 months, p=.016). Eight patients in the dendritic cell vaccine study experienced remarkable long-term, progression-free survival after completing the vaccine therapy, even though they had widely metastatic disease and/or repeated appearance of new metastases despite various therapies. The vaccine treatment was well-tolerated, with most patients experiencing mild skin irritation and redness at the injection site.

"The one-year and projected five-year survival rates of 85% and 54%, respectively, are remarkable for melanoma patients with documented metastatic disease," said Dr. Dillman. "This study is extremely encouraging and shows the potential these types of personalized cancer vaccines have for patients diagnosed with metastatic melanoma."

The study was sponsored by Hoag Hospital Foundation.


Story Source:

The above story is based on materials provided by Hoag Memorial Hospital Presbyterian. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert O. Dillman et al. Phase II Trial of Dendritic Cells Loaded with Antigens from Self-Renewing, Proliferating Autologous Tumor Cells as Patient-Specific Anti-Tumor Vaccines in Patients with Metastatic Melanoma. Cancer Biotherapy and Radiopharmaceuticals, June 2009

Cite This Page:

Hoag Memorial Hospital Presbyterian. "Cancer Vaccines Led To Long-term Survival For Patients With Metastatic Melanoma." ScienceDaily. ScienceDaily, 29 July 2009. <www.sciencedaily.com/releases/2009/07/090728123049.htm>.
Hoag Memorial Hospital Presbyterian. (2009, July 29). Cancer Vaccines Led To Long-term Survival For Patients With Metastatic Melanoma. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2009/07/090728123049.htm
Hoag Memorial Hospital Presbyterian. "Cancer Vaccines Led To Long-term Survival For Patients With Metastatic Melanoma." ScienceDaily. www.sciencedaily.com/releases/2009/07/090728123049.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins